Polyphosphazene polyelectrolytes and uses thereof

Patent metadata

Field	Value
Publication number	US-10858483-B2
Application number	US-201716314735-A
Country	US
Kind code	B2
Filing date	Jul 6, 2017
Priority date	Jul 6, 2016
Publication date	Dec 8, 2020
Grant date	Dec 8, 2020

Abstract

Polyphosphazenes polyelectrolytes. The polyphosphazenes can be prepared by substituting pendant groups (e.g., ionic groups or pendant groups that can form ionic groups) onto a reactive macromolecular precursor for example, by reaction between the reactive chlorine atoms on the backbone of poly(dichlorophosphazene) and appropriate organic nucleophiles. In certain examples, one or more charged pendant groups of a polyphosphazene is/are further modified to introduce desired counterions, which can be hydrophobic counterions. The polyphosphazenes can activate distinct Toll-Like Receptors (TLRs) and can be used in methods of stimulating an immune response.

First claim

What is claimed is:

1. A method of stimulating an immune response in an individual in need thereof, comprising administering to said individual, a polyphosphazene having the following structure:

wherein R − is defined as being an anionic group independently selected from the group consisting of a carboxylate group, a sulfonate group, and a phosphonate group; wherein at least one of the Y + groups in the polyphosphazene is a cationic group independently selected from the group consisting of: N-protonated spermine group, N-protonated spermidine group, N-protonated imidazoquinoline, N-protonated substituted imidazoquinoline group, N- and/or S-protonated thiaimidazoquinoline group, and N- and/or S-protonated substituted thiaimidazoquinoline group, wherein the remaining Y + groups of the polyphosphazene are independently selected from the group consisting of: H + , Na + , K + , Ca 2+ , N-protonated spermine group, N-protonated spermidine group, N-protonated imidazoquinoline, N-protonated substituted imidazoquinoline group, N- and/or S-protonated thiaimidazoquinoline group, and N- and/or S-protonated substituted thiaimidazoquinoline group, and wherein “n” is an integer ranging from 10 to 500,000.

2. The method of claim 1 , wherein one or more Y + is:

wherein
R 1 is independently at each occurrence in the polyphosphazene is —H,

and
R 2 is independently at each occurrence in the polyphosphazene is —H, —CH 3 or CH 2 —CH 2 —CH 3 ,

3. The method of claim 2 , wherein one or more Y + is:

4. The method of claim 1 , wherein the polyphosphazene is present in a composition.

5. The method of claim 1 , wherein the composition comprises a polyphosphazene and a pharmaceutically acceptable carrier.

6. The method of claim 1 , wherein the composition comprises a polyphosphazene, vaccine antigen and, optionally, a pharmaceutically acceptable carrier.

7. The method of claim 1 , wherein the composition comprises a polyphosphazene, an immunomodulating compound and/or TLR agonist, and, optionally, a pharmaceutically acceptable carrier.

8. The method of claim 1 , wherein stimulation of the immune response comprises synergistic production of tumor necrosis factor alpha (TNF-α).

Assignees

• Univ Maryland

Inventors

• Andrianov Alexander K
• Fuerst Thomas R
• Fusco Peter
• Marin Alexander

Classifications

• A61K39/00

  Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title

• A61P37/04 Primary

  Immunostimulants · CPC title

• C08G79/025 Primary

  Polyphosphazenes · CPC title

• A61K39/39

  characterised by the immunostimulating additives, e.g. chemical adjuvants · CPC title